NCT01489722View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients

PHASE1TerminatedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

AZD1208

Daily oral doses of AZD1208 for 28 day cycles until progression or unacceptable toxicity develops. Starting dose will be 120 mg and will be escalated in successive cohorts until an MTD is established.

Trial Locations (4)

Unknown

Research Site, Boston

Research Site, St Louis

Research Site, Houston

Research Site, Toronto

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY